nach oben

Erschienen in:

01.07.2021 | News item

EMA assessing safety of anakinra in adults with COVID-19

Erschienen in: Reactions Weekly | Ausgabe 1/2021

Einloggen, um Zugang zu erhalten

Excerpt

The European Medicines Agency (EMA) has started an evaluation of an application to extend the use of the immunosuppressant anakinra (Kineret) to adults with COVID-19 and pneumonia who are at risk of developing severe respiratory failure. It is assessing the safety and efficacy of anakinra in hospitalised patients with COVID-19. …

EMA. EMA starts evaluating the use of Kineret in adult COVID-19 patients at increased risk of severe respiratory failure Internet Document : 19 Jul 2021. Available from: URL: https://www.ema.europa.eu/en/news/ema-starts-evaluating-use-kineret-adult-covid-19-patients-increased-risk-severe-respiratory-failure

Titel: EMA assessing safety of anakinra in adults with COVID-19
Publikationsdatum: 01.07.2021
Verlag: Springer International Publishing
Erschienen in: Reactions Weekly / Ausgabe 1/2021
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-021-99698-3

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

EMA assessing safety of anakinra in adults with COVID-19

Excerpt

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2021

Lopinavir/ritonavir/umifenovir

Bevacizumab

Ganirelix/ovarian follicle stimulants

Multiple drugs

Multiple drugs

Oxaliplatin